Definium Therapeutics Beheer
Beheer criteriumcontroles 1/4
De CEO Definium Therapeutics is Rob Barrow, benoemd in Jun2021, heeft een ambtstermijn van 5.25 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 12.77M, bestaande uit 5.1% salaris en 94.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.89% van de aandelen van het bedrijf, ter waarde $ 48.34M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.8 jaar en 4.9 jaar.
Belangrijke informatie
Rob Barrow
Algemeen directeur
US$12.8m
Totale compensatie
| Percentage CEO-salaris | 5.13% |
| Dienstverband CEO | 5.3yrs |
| Eigendom CEO | 0.9% |
| Management gemiddelde ambtstermijn | 1.8yrs |
| Gemiddelde ambtstermijn bestuur | 4.9yrs |
Recente managementupdates
Recent updates
Narratiefupdate • Sep 04
DFTX: Phase 3 Mood Disorder Wins And Psychedelic Policy Should Drive Returns
Analysts have nudged their fair value estimate for Definium Therapeutics to $52 from $50, citing stronger assumptions around DT120’s revenue potential and margins after a series of higher price targets across the Street, following positive Phase 3 data in major depressive disorder and generalized anxiety disorder. Analyst Commentary Street research on Definium Therapeutics over the past several months has clustered around one core theme.
Narratiefupdate • Aug 21
DFTX: Phase 3 Mood Disorder Data Will Recast Psychedelic Treatment Potential
Definium Therapeutics' analyst fair value estimate has moved from $59.47 to $67.47 as analysts factor in stronger Phase 3 data for DT120 in major depressive disorder and generalized anxiety disorder, updated approval probabilities, and larger modeled commercial opportunities reflected in a series of higher Street price targets. Analyst Commentary Street research on Definium Therapeutics has shifted noticeably in recent months, with several firms updating valuation models for DT120 in major depressive disorder and generalized anxiety disorder following Phase 3 data and capital raising activity.Seeking Alpha • Aug 12
Definium Therapeutics: 'Strong Buy' On Positive DT120 ODT Data, Two Indications, And September 2026 Catalyst
Summary Definium Therapeutics remains a 'Strong Buy' following positive phase 3 VOYAGE data for DT120 ODT in generalized anxiety disorder [GAD]. The company's DT120 ODT achieved a statistically significant -5.4 placebo-adjusted reduction in HAM-A score at 12 weeks in GAD, highlighting best-in-class potential. Upcoming catalysts include phase 3 PANORAMA GAD data in September 2026 and ASCEND MDD topline results in 2027. The company is well-capitalized with $1.1B in cash, supporting operations into 2030 and multiple late-stage neuropsychiatric programs. Read the full article on Seeking AlphaNarratiefupdate • Aug 07
DFTX: Phase 3 Mood Disorder Data And Psychedelic Policy Will Shape Returns
Analysts lifted their fair value estimate for Definium Therapeutics to $50, citing a series of higher Street price targets in the $57 to $74 range. These targets reflect increased conviction in DT120 following strong Phase 3 data in major depressive disorder and generalized anxiety disorder, a wider anticipated patient footprint, and a regulatory backdrop that is viewed as more supportive for psychedelic treatments.Narratiefupdate • Jul 24
DFTX: Phase 3 Depression Success Will Recast Psychedelic Treatment Potential
Analysts have raised their fair value estimate for Definium Therapeutics from about $35.23 to roughly $59.47, citing increased confidence in DT120 following Phase 3 major depressive disorder data, as well as a more favorable regulatory stance on psychedelic therapies, as key factors behind the higher price targets across the Street. Analyst Commentary Street commentary on Definium Therapeutics centers on how DT120's Phase 3 data in major depressive disorder feeds into valuation, execution risk, and the broader outlook for psychedelic-based therapies.
Narratiefupdate • Jul 10
DFTX: Phase 3 Depression Data Will Drive Repricing Of Psychedelic Franchise
Definium Therapeutics' analyst fair value estimate has moved from about $63.18 to $72.73. This reflects analysts' updated price targets around $57 to $74 after stronger than expected DT120 Phase 3 data in major depressive disorder and generalized anxiety disorder indications, as well as model changes following the recent $805m capital raise.Narratiefupdate • Jun 26
DFTX: Phase 3 Depression Data Will Likely Prove Priced In
Definium Therapeutics' updated fair value estimate has moved from $20.00 to about $35.66 as analysts raise price targets into the $57 to $74 range, citing strong Phase III EMERGE data for DT120 in major depressive disorder and increased confidence in the program across additional indications. Analyst Commentary Recent Street research on Definium Therapeutics centers on the Phase III EMERGE data for DT120 in major depressive disorder, with multiple firms updating their models and adjusting price targets to reflect the reported effect size, durability of response, and safety profile.Nieuw narratief • Apr 02
Phase III Psychedelic Readouts And Breakthrough Status Will Reshape Anxiety And Depression Treatment
Catalysts About Definium Therapeutics Definium Therapeutics is a biopharmaceutical company focused on developing psychedelics-based medicines for generalized anxiety disorder, major depressive disorder and autism spectrum disorder. What are the underlying business or industry changes driving this perspective?Nieuw narratief • Mar 19
Pivotal Phase III Readouts And Breakthrough Status Will Redefine Psychedelic Psychiatry Potential
Catalysts About Definium Therapeutics Definium Therapeutics develops late stage psychedelic based therapies targeting psychiatric and neurodevelopmental disorders. What are the underlying business or industry changes driving this perspective?Nieuw narratief • Mar 04
Psychedelic Trial Setbacks And Costly REMS Model Will Test This Long Term Opportunity
Catalysts About Definium Therapeutics Definium Therapeutics is a biopharmaceutical company focused on developing psychedelic based treatments for generalized anxiety disorder, major depressive disorder and autism spectrum disorder. What are the underlying business or industry changes driving this perspective?Seeking Alpha • Apr 21
Mind Medicine: Initiating Hold Rating Due To Regulatory Challenges
Summary Initiating coverage on Mind Medicine with a Hold rating due to regulatory uncertainties around rescheduling Schedule I compounds for medical use. Despite strong cash resources and promising Phase 3 trials, regulatory delays could hinder MNMD's patient access and market entry. The global GAD, MDD, and ASD markets present significant growth opportunities, but MM120 faces competition and unique safety and scheduling issues. Positive Phase 3 outcomes could drive regulatory progress, but until FDA and DEA clear rescheduling, broad patient access and reimbursement remain uncertain. Read the full article on Seeking AlphaSeeking Alpha • Jan 29
MindMed's LSD Anxiety Drug: Revisiting, Rethinking, But Maintaining My 'Hold' Call
Summary Mind Medicine (MindMed) Inc.'s stock has surged over 160% since my October 2022 “Hold” call, driven by positive Phase 2b data for MM120 in treating GAD. Despite financial stability and promising Phase 3 trials, significant hurdles remain, including DEA rescheduling of LSD and FDA approval challenges. The company faces issues with patenting naturally occurring substances and potential reluctance from insurers and physicians to adopt psychedelic therapies. While MindMed shows progress, I remain cautious due to regulatory and commercial obstacles, maintaining my “Hold” rating on MNMD amidst ongoing uncertainties. Read the full article on Seeking AlphaSeeking Alpha • Nov 04
Mind Medicine: Two Pathways Created From One Pipeline Clinical Candidate
Summary Mind Medicine (MindMed) Inc. is advancing MM-120 for GAD with two phase 3 trials, VOYAGE and PANORAMA, starting in late 2024 and early 2025. MM-120 is also being tested for MDD in the phase 3 EMERGE study, starting in the first half of 2025, with data expected in late 2026. The company has secured funding through 2027, following a public offering, and burns approximately $24.5 million in cash per quarter. Investors should watch for key milestones in 2026 and consider risks related to trial outcomes and regulatory approval for MM-120 and MM-402. Read the full article on Seeking AlphaSeeking Alpha • Aug 15
Psychedelic Stocks: Focus On Their Cash
Summary Jason Najum covers the psychedelic space and contextualizes recent news around the FDA, MDMA, PTSD, and Lykos Therapeutics. Why it may be a blessing in disguise for Cybin, COMPASS Pathways, and MindMed despite setbacks. Major players in the psychedelic medicine space are well-funded, moving into Phase 3 trials, with potential for significant milestones in the near future. Read the full article on Seeking AlphaSeeking Alpha • Jun 05
MindMed: Despite MDMA Setback, Still Hope In Light Of Differentiating Factors
Summary Mind Medicine's (MindMed) results from phase 1 investigator-initiated trial, using MM-402 for the treatment of patients with Autism Spectrum Disorder, expected Q2 of 2024. The primary endpoint of the phase 2b MMED008 study met with statistical significance of HAM-A score over a 4-week period; Patients were given MM-120 to treat GAD. The global Generalized Anxiety Disorder treatment market is expected to reach $4.26 billion by 2033. MindMed has a backup candidate in its pipeline, MM-402, which still uses MDMA targeting for disorders, but with an improved safety profile; this would be MDMA types R[-]-MDMA, S[+]-MDMA and R/S-MDMA. Read the full article on Seeking AlphaSeeking Alpha • Apr 04
Mind Medicine: GAD Program Success Continues With BTD And Positive Treatment Data
Summary Mind Medicine (MindMed) Inc. achieved positive results from phase 2b MMED008 study using MM-120 for the treatment of patients with generalized anxiety disorder. End-of-phase 2 meeting with the FDA for MM-120 program for GAD 1st half of 2024 and phase 3 trial initiation expected 2nd half of 2024. The global generalized anxiety disorder treatment market is expected to reach $4.26 billion by 2033. MM-402 is being advanced in a phase 1 study for the treatment of patients with ASD with results expected 1st half of 2024; The global autism spectrum disorder market could grow to $3.42 billion by 2030. Read the full article on Seeking AlphaAnalyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$354m |
| Mar 31 2026 | n/a | n/a | -US$238m |
| Dec 31 2025 | US$13m | US$655k | -US$184m |
| Sep 30 2025 | n/a | n/a | -US$168m |
| Jun 30 2025 | n/a | n/a | -US$115m |
| Mar 31 2025 | n/a | n/a | -US$78m |
| Dec 31 2024 | US$3m | US$624k | -US$109m |
| Sep 30 2024 | n/a | n/a | -US$98m |
| Jun 30 2024 | n/a | n/a | -US$102m |
| Mar 31 2024 | n/a | n/a | -US$125m |
| Dec 31 2023 | US$2m | US$599k | -US$96m |
| Sep 30 2023 | n/a | n/a | -US$77m |
| Jun 30 2023 | n/a | n/a | -US$75m |
| Mar 31 2023 | n/a | n/a | -US$63m |
| Dec 31 2022 | US$5m | US$672k | -US$57m |
| Sep 30 2022 | n/a | n/a | -US$69m |
| Jun 30 2022 | n/a | n/a | -US$69m |
| Mar 31 2022 | n/a | n/a | -US$98m |
| Dec 31 2021 | US$12m | US$350k | -US$93m |
Compensatie versus markt: De totale vergoeding ($USD 12.77M ) Rob } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 8.43M ).
Compensatie versus inkomsten: De vergoeding van Rob is gestegen terwijl het bedrijf verliesgevend is.
CEO
Rob Barrow (37 yo)
5.3yrs
Tenure
US$12,767,442
Compensatie
Mr. Robert Barrow, also known as Rob, serves as Chief Executive Officer at Mind Medicine (MindMed) Inc since June 9, 2021 and serves a its Director since December 13, 2021. He served as Chief Development O...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Director | 5.3yrs | US$12.77m | 0.89% $ 48.3m | |
| Chief Financial Officer | 1.3yrs | US$5.33m | 0.098% $ 5.3m | |
| Chief Medical Officer | 5.6yrs | US$4.00m | 0.45% $ 24.3m | |
| Co-Founder & Clinical Advisor | no data | US$501.19k | geen gegevens | |
| Co-Founder | no data | geen gegevens | geen gegevens | |
| Senior Vice President of Pharmaceutical Development & Operations | 1.7yrs | geen gegevens | geen gegevens | |
| VP & Head of Investor Relations | no data | geen gegevens | geen gegevens | |
| Chief Legal Officer & Corporate Secretary | 3.4yrs | US$1.16m | 0.093% $ 5.0m | |
| Vice President of Corporate Communications | 1.3yrs | geen gegevens | geen gegevens | |
| Chief Corporate Affairs Officer | 2.2yrs | geen gegevens | geen gegevens | |
| Chief Regulatory & Quality Assurance Officer | 1.8yrs | geen gegevens | geen gegevens | |
| Chief Commercial Officer | 1.5yrs | geen gegevens | 0.27% $ 14.6m |
1.8yrs
Gemiddelde duur
53yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van DFTX wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.8 jaar), wat duidt op een nieuw team.
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Director | 4.8yrs | US$12.77m | 0.89% $ 48.3m | |
| Independent Chairperson | 5yrs | US$496.83k | 0.012% $ 665.8k | |
| Independent Director | 3.3yrs | US$458.83k | 0.0079% $ 427.3k | |
| Independent Director | 4.1yrs | US$457.83k | 0.015% $ 789.6k | |
| Chair of Scientific Advisory Board | 5.5yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 5.1yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 5.3yrs | geen gegevens | geen gegevens | |
| Independent Vice Chairman | 5yrs | US$484.83k | 0.011% $ 607.9k | |
| Independent Director | 4.1yrs | US$456.83k | 0.015% $ 789.6k | |
| Member of Scientific Advisory Board | 1.9yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 5.3yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 4.8yrs | geen gegevens | geen gegevens |
4.9yrs
Gemiddelde duur
68yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van DFTX wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.9 jaar).
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/09/15 22:06 |
| Aandelenkoers aan het einde van de dag | 2026/09/15 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Definium Therapeutics, Inc. wordt gevolgd door 24 analisten. 15 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Christopher Chen | Baird |
| null null | Baird |
| Joel Beatty | Baird |